SecBot SecBot

ANTX

AN2 Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001880438 Biotech & Drug Discovery
$3.62 +0.07 (+1.83%)
Oct 26 4:00 PM ET · prev $3.55
Market cap
$137.4M
Micro cap
Median target
$9.00
+149% · range $9.00–9.00
Next earnings
Nov 5
in 10 days · EPS est. −$0.20
1 year
+167.8%
from $1.35 · Oct 27
30 days
−27.8%
from $5.01
52-week range
$1.03–6.28
−42% from high · low Feb 18
Avg volume 20D
302.0K
shares / day
Short interest
2.49M
≈6.6% of shares · +4.0%
Days to cover
9.5
at average volume
Insider net
−$332.6K
1 buyer · 3 sellers · since Mar 19
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1 ·Next Earnings date, Nov 5, 2026
Strongest NEUTRAL AN2 Therapeutics reported Q2 2026 net loss of $8.2M ($0.18/share) vs $6.5M ($0.21/share) in Q2 2025, with…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $11.6K at an average $5.53. 3 insiders sold $344.2K. Price is 35% below their cost.

  • InstitutionsMIXED

    Q2 2026: 7 added (0 new), 7 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.240 → −$0.200 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +4.0% to 2.49M shares. 9.5 days to cover, ≈6.6% of shares.

  • TrendDOWNTREND

    28% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED1,665,494$8.1M
CITADEL ADVISORS LLCDOUBLED951,997$4.6M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED697,806$3.4M
Woodline Partners LPTRIM459,805$2.2M
STATE STREET CORPDOUBLED311,602$1.5M
NORTHERN TRUST CORPDOUBLED214,921$1.0M
VANGUARD FIDUCIARY TRUST COADD196,920$953.1K
BANK OF AMERICA CORP /DE/TRIM145,803$705.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jul 2026
12-month targets · 2 analysts

Price is below the lowest target. Median implies +149%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Jul 20, 2026Guggenheim
INITIATE
INITIATEBuy
May 14, 2026Leerink Partners
UPGRADE
UPGRADEOutperform
Reddit

Fresh Reddit data

The last 24 hours of Reddit activity are for subscribers.

Subscribe for Full Access
Recent posts
r/smallstreetbets20h ago
Fresh post, for subscribers
Recent comments
r/pennystocks20h ago
Fresh comment, for subscribers
All social signals and their track records

Insider ledger

Form 4
$11.6K
bought · 1 insider
$344.2K
sold · 3 insiders
−34.6%
vs their $5.53 cost
DateInsiderTypeValue
Oct 12, 2026
Marks Gilbert Lynn
Director
AWARD2,283 sh
Oct 12, 2026
Aziz Kabeer
Director
AWARD2,465 sh
Oct 12, 2026
Martin Patricia A.
Director
AWARD389 sh
Sep 15, 2026
Trenor Cameron C. III
Chief Medical Officer
AWARD116,667 sh
Sep 15, 2026
Trenor Cameron C. III
Chief Medical Officer
AWARD233,333 sh
Sep 9, 2026
Readnour Robin Shane
Director
SELL$3.2K
Sep 9, 2026
Readnour Robin Shane
Director
SELL$3.5K
Sep 8, 2026
Readnour Robin Shane
Director
SELL$28.4K

Earnings setup

Estimates
Nov 5
reports in 10 days
−$0.20
EPS estimate, this quarter
+17%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.20-$0.20–-$0.20+16.7%$0.00
Next Q-$0.23-$0.26–-$0.21+6.0%$0.00
Current FY-$0.90-$0.93–-$0.86+6.8%$0.00
Next FY-$0.80-$0.86–-$0.74+23.1%$0.00

Short side

FINRA· Sep 30, 2026
2,491,971
shares short
+4.0%
vs prior settlement
9.5
days to cover
≈6.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 12, 2026 Other
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating A
Oct 12, 2026 Insider
Marks Gilbert Lynn was granted 2,283 shares
Director
Oct 12, 2026 Insider
Aziz Kabeer was granted 2,465 shares
Director
Oct 12, 2026 Insider
Martin Patricia A. was granted 389 shares
Director
Aug 11, 2026 SEC
AN2 Therapeutics reported Q2 2026 net loss of $8.2M ($0.18/share) vs $6.5M ($0.21/share) in Q2 2025, with net loss per…
8-K — Impact 4/10
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
1,665,494 shares ($8.1M)
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — DOUBLED
951,997 shares ($4.6M)
Jun 4, 2026 SEC
AN2 Therapeutics reported positive enabling data for its oral CPSF3 inhibitor AN2-502998 in chronic Chagas disease. A…
8-K — Impact 7/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
ANTX Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Oct 12, 2026
Press release
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) on behalf…
Aug 10, 2026
Earnings date
ANTX Q2 2026 Earnings Scheduled — 2026-08-10
Aug 6, 2026
Earnings date
ANTX Q2 2026 Earnings Scheduled — 2026-08-06
Jul 20, 2026
Press release
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)
NEW YORK, July 20, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) on behalf…
Jul 15, 2026
Short interest
Short Interest: ANTX up 27% to 2.4M shares
Settlement 2026-07-15 | Days to cover: 9.90 | ≈6.76% of shares outstanding (est.)

SecBot reports

5 filings · 1 bullish · 1 bearish · 3 neutral
All ANTX filing & press-release reports (5)